Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Splenic Siderosis in Mice Treated with Dithiourethane

Abstract

IN an attempt to elucidate the mode of action of urethane (ethyl carbamate) as a carcinogen for mice, its dithio analogue (NH2CSSC2H5) was prepared1,2 and a study was made of its lethal dose and general toxic effects before testing it for carcinogenicity. A report of the latter is in preparation. The short-term tests revealed an action of this compound whose significance is, at the moment, rather obscure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Campbell, N., and McKail, J. E., J. Chem. Soc., Part II, 1251 (1948).

  2. Delépine, M., Bull. Soc. chim. Paris, 29, 48 (1903).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

COWEN, P. Splenic Siderosis in Mice Treated with Dithiourethane. Nature 184, 366–367 (1959). https://doi.org/10.1038/184366b0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/184366b0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing